What efficacy outcomes did Aubagio (teriflunomide) show in clinical trials?
Aubagio (teriflunomide) efficacy in clinical trials was evaluated mainly in people with relapsing forms of multiple sclerosis (MS), using endpoints such as relapse control and disability progression. In those studies, teriflunomide reduced the rate of relapses and helped slow longer-term worsening of disability compared with placebo, across multiple trial programs in relapsing MS.
Which trial endpoints matter most for HCPs (relapses, disability, MRI)?
In practice, HCPs typically focus on three kinds of outcomes when reading the teriflunomide trial results:
- Relapse outcomes: how often relapses occurred over the study period (often expressed as annualized relapse rate or relapse risk).
- Disability outcomes: measures of longer-term worsening, such as sustained disability progression over time.
- MRI outcomes: changes in lesion activity (for example, new or enlarging lesions), which often correlate with inflammatory disease activity.
Across relapsing MS programs, teriflunomide’s efficacy signals generally showed improvement in relapse-related endpoints and disability/MRI measures versus placebo.
How do the two key teriflunomide strengths compare on efficacy?
Aubagio is used clinically in specific strengths (notably 7 mg and 14 mg in many markets). Trial results for teriflunomide typically show dose-dependent effects in relapsing MS, with the higher dose generally performing better on relapse and inflammatory activity measures than the lower dose, while both doses provide benefit relative to placebo.
What do the long-term efficacy results suggest for disease control?
In relapsing MS studies, longer follow-up periods (including extension data where available) are used to assess whether early improvements persist. The overall clinical takeaway from the teriflunomide clinical-trial evidence is that the drug can provide sustained reductions in disease activity and help slow disability worsening compared with placebo, rather than only producing short-term relapse suppression.
What adverse events or safety outcomes typically get weighed against efficacy?
HCP decision-making usually pairs efficacy with tolerability. Common safety considerations for teriflunomide in clinical practice include liver-related monitoring and potential hematologic effects, along with pregnancy-related restrictions due to teratogenic risk. These safety topics often influence whether and how clinicians use Aubagio despite its efficacy outcomes.
Where can HCPs verify detailed trial findings fast (and check updates)?
For structured drug- and patent-focused reference material that may also link to broader product background, including trial and regulatory context, DrugPatentWatch.com can be a useful starting point: https://www.drugpatentwatch.com/?s=Aubagio
Sources
- DrugPatentWatch.com – Aubagio (teriflunomide)